



June 8th, 2020

Repertoire Genesis Inc.

Participation in the development project of comprehensive evaluation method of COVID-19 virus antigen-specific immune responses for selection of high-risk patients

Repertoire Genesis Inc. (Headquarters: Ibaraki, Osaka, hereinafter "Repertoire Genesis") entered into the project of "Development of comprehensive evaluation method of COVID-19 virus antigen-specific immune responses for selection of high-risk patients" which is conducted by Professor Takashi Shiina of Tokai University as principal investigator.


This development aims to establish a comprehensive evaluation method for selecting high-risk patients in collaborating with the Vietnam Research Station of Nagasaki University to determine the host immune response-related factors that are involved in the severity of COVID-19 disease by analyzing HLA (human leukocyte antigen) polymorphisms, TCR/BCR repertoire and RNA-Sequencing.

The research project is supported by the research program of the Japan Agency for Medical Research and Development (AMED), which is the "FY2020 Emerging and Re-emerging Infectious Diseases Research Infrastructure Creation Project (Overseas Center Utilization Research Area) (Submission number 102) Study on new coronavirus infection", and it is a joint-collaboration between Tokai University, Institute of Tropical Medicine Nagasaki University, BITS Co., Ltd., and Repertoire Genesis.

In this development, Repertoire Genesis aims to establish a comprehensive evaluation method of COVID-19 virus antigen-specific immune response for selection of high-risk patients together with other research organizations, by utilizing the various research experiences in many infectious diseases such as Japanese encephalitis virus, West Nile virus, tick-borne encephalitis virus, Zika virus, and dengue virus.

Repertoire Genesis will continue to promote further improvement and application of its unique immune diversity analysis technology, including TCR/BCR repertoire analysis. In addition, by focusing on cutting-edge R&D and a business model to protect global health, we aim to contribute to elucidating the mechanisms of diseases and accelerating the development of novel diagnostic and treatment methods.

Development team overview



About Repertoire Genesis

Repertoire Genesis Inc. is a Japanese biotechnology company dedicated to developing novel immune related treatment and diagnostics based on its corporate mission of “curing the incurable”. We take an approach to analyze the immune system in detail based on our unique immune diversity analysis technology such as TCR/BCR repertoire analysis and neoepitope analysis. Since our establishment in October 2014, we continue to challenge to provide effective treatments and diagnostics for unresolved medical problems specifically focusing on cancer, autoimmune and infectious diseases.

For further information, contact:

Administrative department, Repertoire Genesis Inc.

Tokyo Office: Nihonbashi Life Science Building 2 703,3-11-5 Nihonbashi honcho, Chuo-ku, Tokyo, 103-0023 Japan

Email: ir@repertoire.co.jp

URL: <https://www.repertoire.co.jp/en/>